Journal Club: All Recent News

Ontario has added Erelzi (etanercept) to public drug plan for the treatment of multiple inflammatory diseases

(Jan 9 2018)

Filing of Patent Infringement Lawsuit Concerning Rituxan Injection, and a Petition for Provisional Disposition Order

(Jan 8 2018)

Novartis advances head-to-head superiority trials of Cosentyx versus Humira and proposed biosimilar adalimumab

(Jan 8 2018)

NeuClone Discloses Details of its Fifth Product: A Biosimilar Candidate for Prolia/XGEVA (Denosumab)

(Jan 8 2018)

Glenmark launches biosimilar Adalimumab in India

(Jan 5 2018)

Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept)

(Jan 3 2018)

Hetero launches the biosimilar ‘Adalimumab’ under the brand name ‘Mabura’ in India

(Jan 2 2018)

Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs

(Dec 28 2017)

Biosimilars need huge investments, longer timelines

(Dec 27 2017)

Clover Biopharmaceuticals Receives CFDA Approval to Initiate Clinical Trials in China with Etanercept Biosimilar Candidate SCB-808

(Dec 22 2017)

Xbrane Biopharma informs about ongoing negotiations concerning out-licensing of Spherotide to China

(Dec 22 2017)

Biocon's biosimilar arm may raise $500 million to fund clinical development

(Dec 21 2017)

JHL Biotech Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis

(Dec 20 2017)

JHL Biotech Submits Clinical Trial Application in Europe for Proposed Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers

(Dec 20 2017)

Selexis SA and Turgut Pharmaceuticals Advance Partnership with Third Commercial License Agreement

(Dec 20 2017)

Samsung Bioepis' SB3 Trastuzumab Biosimilar Candidate Accepted for Review by the US Food and Drug Administration

(Dec 20 2017)

Hikma Reaches Licensing Agreement With Celltrion For Third Biosimilar Product In The Middle East And North Africa

(Dec 19 2017)

Fresenius submits first biosimilar Marketing Authorization Application

(Dec 18 2017)

Celltrion Receives Positive CHMP Opinion for Herzuma for Trastuzumab Biosimilar

(Dec 15 2017)

Univercells secures €3M Series A2 funding

(Dec 15 2017)

Pages